ExEm® Foam Inc. is pleased to be an Exhibitor at the World Class CME Best of the Big Apple 2021 OB-GYN Ultrasound Meeting taking place at the Sheraton Times Square Hotel in Manhattan, New York from November 12 – 14, 2021. Visit the ExEm® Foam booth to view a live educational demonstration of the HyFoSy ultrasound tubal patency procedure using ExEm® Foam ((air polymer-type A) intrauterine foam), an innovative, FDA-approved contrast drug that allows for ultrasound tubal patency testing in women with known or suspected infertility. A European trained sonographer and the co-inventor of ExEm® Foam, Professor Mark Hans Emanuel, M.D., Ph.D. from The Netherlands, will be available to answer product and HyFoSy procedure questions. Stop by to also learn more about new offerings, reimbursement programs, and product ordering.
About World Class CME and the Best of the Big Apple 2021 OB-GYN Ultrasound Meeting
World Class CME, a physician-founded company, provides exceptional continuing medical education in the areas of radiology, breast imaging, OB-GYN ultrasound and gynecology. They offer live and online courses designed for progressive community physician, and other members of the patient care team, including sonographers, radiologic technologists and advanced practitioners.
The Best of the Big Apple 2021 OB-GYN Ultrasound Meeting offers the most relevant and up-do-date OB-GYN Ultrasound information. The course is designed for radiologists, OB-GYN physicians, and sonographers who require ultrasound skills to manage complicated cases.
About ExEm® Foam (air polymer-type A) intrauterine foam
ExEm® Foam ((air polymer-type A) intrauterine foam) is an innovative, FDA-approved product that offers a less invasive ultrasound procedure, a highly accurate alternative to other tubal patency assessment procedures, like laparoscopy or X-ray HSG. The contrast agent allows for easy recognition of tubal patency using the Foam procedure. During the tubal patency procedure, the foam is infused into the uterus by a healthcare professional to allow for visual assessment of fallopian tubes. If the tubes are patent the foam will appear as a thin, bright white line within the fallopian tubes and spill over the ovaries and into the peritoneal cavity when visualized with ultrasound. If the white line does not appear, the fallopian tubes might be occluded or blocked.
IMPORTANT SAFETY INFORMATION
ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.
Click here for full prescribing information.
About ExEm® Foam Inc
ExEm® Foam Inc is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm® Foam has been used in more than 500,000 tubal patency procedures worldwide since it first launched in Europe in 2011. ExEm® Foam Inc is headquartered in Nashville, TN.
For more information, please visit www.ExEmFoam.com.
